OBJECTIVE: To analyse survival of HIV-infected patients who developed cytomegalovirus (CMV) disease and to identify prognostic factors of their survival. METHODS: Cases of CMV disease diagnosed in the Aquitaine Cohort of HIV-infected patients (n = 4297) during the 1986-1996 period, were reviewed using standardised definitions. Follow-up was extended to December 1997. Cox model was used to determine factors associated with survival after the initial manifestations of CMV disease, considering protease inhibitor (PI) prescription and anti-CMV treatment as time dependent covariates. RESULTS: 253 patients presented a CMV disease of which 221 (87.3%) died (median survival: 7 months). A better prognosis for survival was associated with: PI prescription [relative hazard (RH): 0.26; 95% confidence interval (CI): 0.11-0.59], anti-CMV treatment (RH: 0.37; CI: 0.25-0.54), CD4+ lymphocyte cell count > 50/mm3 (RH: 0.66; CI: 0.47-0.94) and absence of neoplasia (RH: 0.70; CI: 0.52-0.94) whereas the disseminated CMV disease worsened prognosis (RH: 1.83; CI: 1.20-2.80). CONCLUSION: Antiretroviral treatment including PI, improved short-term prognosis of CMV disease regardless of its clinical manifestations.
OBJECTIVE: To analyse survival of HIV-infectedpatients who developed cytomegalovirus (CMV) disease and to identify prognostic factors of their survival. METHODS: Cases of CMV disease diagnosed in the Aquitaine Cohort of HIV-infectedpatients (n = 4297) during the 1986-1996 period, were reviewed using standardised definitions. Follow-up was extended to December 1997. Cox model was used to determine factors associated with survival after the initial manifestations of CMV disease, considering protease inhibitor (PI) prescription and anti-CMV treatment as time dependent covariates. RESULTS: 253 patients presented a CMV disease of which 221 (87.3%) died (median survival: 7 months). A better prognosis for survival was associated with: PI prescription [relative hazard (RH): 0.26; 95% confidence interval (CI): 0.11-0.59], anti-CMV treatment (RH: 0.37; CI: 0.25-0.54), CD4+ lymphocyte cell count > 50/mm3 (RH: 0.66; CI: 0.47-0.94) and absence of neoplasia (RH: 0.70; CI: 0.52-0.94) whereas the disseminated CMV disease worsened prognosis (RH: 1.83; CI: 1.20-2.80). CONCLUSION: Antiretroviral treatment including PI, improved short-term prognosis of CMV disease regardless of its clinical manifestations.
Authors: B S Peters; E J Beck; S Anderson; D Coleman; R Coker; J Main; C Migdal; J R Harris; A J Pinching Journal: J Infect Date: 1991-09 Impact factor: 6.072
Authors: C E O'Sullivan; W L Drew; D J McMullen; R Miner; J Y Lee; R A Kaslow; J G Lazar; M S Saag Journal: J Infect Dis Date: 1999-09 Impact factor: 5.226
Authors: A G Palestine; M A Polis; M D De Smet; B F Baird; J Falloon; J A Kovacs; R T Davey; J J Zurlo; K M Zunich; M Davis Journal: Ann Intern Med Date: 1991-11-01 Impact factor: 25.391
Authors: I Cheong; P J Flegg; R P Brettle; P D Welsby; S M Burns; B Dhillon; C L Leen; J A Gray Journal: Int J STD AIDS Date: 1992 Sep-Oct Impact factor: 1.359
Authors: Nini Tun; Nikolas London; Moe Kyaw Kyaw; Frank Smithuis; Nathan Ford; Todd Margolis; W Lawrence Drew; Susan Lewallen; David Heiden Journal: J Int AIDS Soc Date: 2011-08-15 Impact factor: 5.396
Authors: Paulina Ocieczek; James R Barnacle; Joe Gumulira; Sam Phiri; Tom Heller; Iwona Grabska-Liberek Journal: Open Forum Infect Dis Date: 2019-11-06 Impact factor: 3.835
Authors: David Heiden; Nathan Ford; David Wilson; William R Rodriguez; Todd Margolis; Bart Janssens; Martha Bedelu; Nini Tun; Eric Goemaere; Peter Saranchuk; Kalpana Sabapathy; Frank Smithuis; Emmanuel Luyirika; W Lawrence Drew Journal: PLoS Med Date: 2007-12 Impact factor: 11.069